Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

A machine learning approach for somatic mutation discovery.

Wood DE, White JR, Georgiadis A, Van Emburgh B, Parpart-Li S, Mitchell J, Anagnostou V, Niknafs N, Karchin R, Papp E, McCord C, LoVerso P, Riley D, Diaz LA Jr, Jones S, Sausen M, Velculescu VE, Angiuoli SV.

Sci Transl Med. 2018 Sep 5;10(457). pii: eaar7939. doi: 10.1126/scitranslmed.aar7939.

2.

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, Mussolin B, Baldi F, Buscarino M, Bartolini A, Valtorta E, Vidal J, Bellosillo B, Germano G, Pietrantonio F, Ponzetti A, Albanell J, Siena S, Sartore-Bianchi A, Di Nicolantonio F, Montagut C, Bardelli A.

Nat Commun. 2016 Dec 8;7:13665. doi: 10.1038/ncomms13665.

3.

TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells.

Hobor S, Van Emburgh BO, Crowley E, Misale S, Di Nicolantonio F, Bardelli A.

Clin Cancer Res. 2014 Dec 15;20(24):6429-38. doi: 10.1158/1078-0432.CCR-14-0774. Epub 2014 Jun 10.

4.

Acquired resistance to EGFR-targeted therapies in colorectal cancer.

Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A.

Mol Oncol. 2014 Sep 12;8(6):1084-94. doi: 10.1016/j.molonc.2014.05.003. Epub 2014 May 14. Review.

5.

Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer.

Smith TR, Liu-Mares W, Van Emburgh BO, Levine EA, Allen GO, Hill JW, Reis IM, Kresty LA, Pegram MD, Miller MS, Hu JJ.

Carcinogenesis. 2011 Sep;32(9):1354-60. doi: 10.1093/carcin/bgr117. Epub 2011 Jun 23.

6.

Modulation of Dnmt3b function in vitro by interactions with Dnmt3L, Dnmt3a and Dnmt3b splice variants.

Van Emburgh BO, Robertson KD.

Nucleic Acids Res. 2011 Jul;39(12):4984-5002. doi: 10.1093/nar/gkr116. Epub 2011 Mar 4.

7.

A novel DNMT3B splice variant expressed in tumor and pluripotent cells modulates genomic DNA methylation patterns and displays altered DNA binding.

Gopalakrishnan S, Van Emburgh BO, Shan J, Su Z, Fields CR, Vieweg J, Hamazaki T, Schwartz PH, Terada N, Robertson KD.

Mol Cancer Res. 2009 Oct;7(10):1622-34. doi: 10.1158/1541-7786.MCR-09-0018. Epub 2009 Oct 13.

8.

DNA methylation in development and human disease.

Gopalakrishnan S, Van Emburgh BO, Robertson KD.

Mutat Res. 2008 Dec 1;647(1-2):30-8. doi: 10.1016/j.mrfmmm.2008.08.006. Epub 2008 Aug 20. Review.

9.

Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer.

Van Emburgh BO, Hu JJ, Levine EA, Mosley LJ, Perrier ND, Freimanis RI, Allen GO, Rubin P, Sherrill GB, Shaw CS, Carey LA, Sawyer LR, Miller MS.

Oncol Rep. 2008 May;19(5):1311-21.

10.

DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.

Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD.

Mol Cell Biol. 2008 Jan;28(2):752-71. Epub 2007 Nov 8.

11.

Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer.

Van Emburgh BO, Hu JJ, Levine EA, Mosley LJ, Case LD, Lin HY, Knight SN, Perrier ND, Rubin P, Sherrill GB, Shaw CS, Carey LA, Sawyer LR, Allen GO, Milikowski C, Willingham MC, Miller MS.

Mol Carcinog. 2008 Feb;47(2):88-99.

12.

Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma.

Arbiser JL, Fan CY, Su X, Van Emburgh BO, Cerimele F, Miller MS, Harvell J, Marinkovich MP.

J Invest Dermatol. 2004 Oct;123(4):788-90.

Supplemental Content

Loading ...
Support Center